Ernexa Therapeutics Inc.

Contributing Author

Recent Articles by Ernexa Therapeutics Inc.

4 hours	Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer ERNA GlobeNewswire
Dec-03	Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting ERNA GlobeNewswire
Dec-02	Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG ERNA GlobeNewswire
Nov-11	Ernexa Therapeutics to Present at Oxford Global's Cell 2025 ERNA GlobeNewswire
Nov-10	Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials ERNA GlobeNewswire
Nov-06	Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor "What This Means" Platform ERNA GlobeNewswire
Oct-01	Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa ERNA GlobeNewswire
Sep-29	Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit ERNA GlobeNewswire
Sep-17	Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research ERNA GlobeNewswire
Sep-10	Ernexa Therapeutics Provides Update on Operational Excellence and Performance ERNA GlobeNewswire
Sep-03	Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference ERNA GlobeNewswire
Jul-09	Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements ERNA GlobeNewswire
Jun-25	Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development ERNA GlobeNewswire
Jun-24	Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement ERNA GlobeNewswire
Jun-10	Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split ERNA GlobeNewswire
May-28	Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 ERNA GlobeNewswire
May-14	Ernexa Therapeutics Establishes Texas Subsidiary to Support Continued Development of ERNA-101 and Future Clinical Operations ERNA GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.